Patient specific treatment sequencing in ER plus advanced breast cancer

被引：0
|
作者：
Johnston, Stephen [1 ,2 ,3 ]
机构：
[1] Royal Marsden NHS Fdn Trust, Breast Canc Med, London, England
[2] Royal Marsden NHS Fdn Trust, London, England
[3] Inst Canc Res, London, England
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2020年 / 180卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：590 / 590
页数：1
相关论文
共 50 条
  • [31] Pathophysiological role of NNAT in ER plus breast cancer
    Semenikhina, Marharyta
    Plasterer, Cody
    Tsaih, Shirng-Wern
    Flister, Michael
    Palygin, Oleg
    FASEB JOURNAL, 2022, 36
  • [32] Low ER plus Breast Cancer Is This a Distinct Group?
    Gloyeske, Nika C.
    Dabbs, David J.
    Bhargava, Rohit
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 141 (05) : 697 - 701
  • [33] Mechanisms of therapeutic resistance in ER plus breast cancer
    Clarke, R. B.
    CANCER RESEARCH, 2021, 81 (04)
  • [34] New treatments for ER plus breast cancer.
    Chang, SB
    Miron, P
    Kung, AL
    Miron, A
    Iglehart, JD
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S251 - S251
  • [35] The shared genetic landscape of polycystic ovary syndrome and breast cancer: convergence on ER plus breast cancer but not ER- breast cancer
    Bi, Kaixin
    Chen, Miaoran
    Zhao, Qianru
    Yang, Tongtong
    Xie, Wenjia
    Ma, Wenqi
    Jia, Hongyan
    BREAST CANCER RESEARCH, 2024, 26 (01)
  • [36] RSK as a Therapeutic Target for ER plus Breast Cancer
    Faltas, Christina
    Holz, Marina K.
    FASEB JOURNAL, 2022, 36
  • [37] Treatment and treatment considerations in a patient with advanced breast cancer and acute intermittent porphyria
    Kristiansen, C
    Langkjer, ST
    ACTA ONCOLOGICA, 2006, 45 (03) : 337 - 339
  • [38] Safety and pharmacokinetics of vepdegestrant in Japanese patients with ER plus advanced breast cancer: a phase 1 study
    Iwata, Hiroji
    Naito, Yoichi
    Hattori, Masaya
    Yoshimura, Akiyo
    Yonemori, Kan
    Aizawa, Mana
    Mori, Yuko
    Yoshimitsu, Junichiro
    Umeyama, Yoshiko
    Mukohara, Toru
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, 30 (01) : 72 - 82
  • [39] Novel Agents Show Promise Against Acquired Endocrine Resistance in ER plus Advanced Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S15 - S16
  • [40] Evaluation of RAD1901, a novel investigational, selective estrogen receptor degrader (SERD), for the treatment of ER-positive (ER plus ) advanced breast cancer.
    Bardia, Aditya
    Kabos, Peter
    Elledge, Richard
    Wang, Dannie
    Shen, Jinshan
    Garner, Fiona
    O'Neill, Alison
    Kaklamani, Virginia G.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345